J
Jean-Jacques Grob
Researcher at Aix-Marseille University
Publications - 369
Citations - 58038
Jean-Jacques Grob is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Medicine & Melanoma. The author has an hindex of 71, co-authored 310 publications receiving 45788 citations. Previous affiliations of Jean-Jacques Grob include University of Sydney.
Papers
More filters
Journal Article
Influence of sun exposure after childhood on the development of nevi: a study in monozygotic twins
F. Roudil,Jean-Jacques Grob,J. Gouvernet,M. A. Richard-Lallemand,N. Basseres,J.-J. Bonerandi +5 more
TL;DR: Intrapair differences in the number of nevi on never-exposed areas raises the possibility of either a systemic effect of sun exposure or other yet unidentified environmental risk factors for the development of neVI.
Journal ArticleDOI
Safety and results of anti-PD1 combined with radiosurgery for the treatment of melanoma brain metastases.
Caroline Gaudy Marqueste,Romain Carron,Florent Amatore,N. Malissen,Xavier Muracciole,Anderson Loundou,L. Troin,Sandrine Monestier,Stéphanie Mallet,Marie-Aleth Richard,Jean Régis,Jean-Jacques Grob +11 more
TL;DR: Retrospective assessment of the interaction between Gamma-Knife radiosurgery (GKRS) and anti-PD1 in terms of toxicity and OS in mm patients (pts) with BM finds one pt died before radiological evaluation.
Journal ArticleDOI
First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients with in transit melanoma.
Christophe Le Tourneau,Brigitte Dréno,Youlia M. Kirova,Jean-Jacques Grob,Thomas Jouary,Caroline Dutriaux,Luc Thomas,Céleste Lebbé,Laurent Mortier,Philippe Saiag,Marie-Françoise Avril,Eve Maubec,Pierre Bey,Jean-Marc Cosset,Jian-Sheng Sun,Bernard Asselain,Flavien Devun,Michel Marty,Marie Dutreix +18 more
TL;DR: DT01 is a double stranded DNA oligonucleotide conjugated to cholesterol, which mimics "false" double strand breaks (DSB) which triggers DNA repair proteins trapping, thereby inhibiting their repair activity.
Proceedings ArticleDOI
Abstract PR-1: AGENDA: Results of a randomized, double‐blind phase III trial of dacarbazine with or without Bcl‐2 targeted therapy (oblimersen) in a biomarker‐defined patient population with advanced melanoma
Céleste Lebbé,Agop Y. Bedikian,Jean-Jacques Grob,Caroline Robert,Brigitte Dréno,Sanjiv S. Agarwala,Claus Garbe +6 more
TL;DR: A randomized trial in patients with advanced melanoma showed OBL plus dacarbazine (DTIC) significantly increased progression‐free survival (PFS) plus overall, durable, and complete response rates and an independent analysis of an EORTC study showed that this negative correlation extended into the upper limit of the normal range (ULN).
Journal Article
Valeurs cinetiques de la lymphoscintigraphie du ganglion sentinelle dans les melanomes malins cutanes cervico-faciaux.
TL;DR: Evaluating the lymphoscintigraphy appearance time (LAT) of the sentinel lymph node (SLN) in head and neck cutaneous melanoma to determine whether a correlation exists between LAT and SLN status (negativity or positivity) found a recurrence was significantly observed.